These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29775157)

  • 1. Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA.
    Duffy MJ; McDermott EW; Crown J
    Tumour Biol; 2018 May; 40(5):1010428318776169. PubMed ID: 29775157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Circulating proteinic biomarkers and breast cancer].
    Mathelin C; Koehl C; Rio MC
    Gynecol Obstet Fertil; 2006; 34(7-8):638-46. PubMed ID: 16876456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.
    Appierto V; Di Cosimo S; Reduzzi C; Pala V; Cappelletti V; Daidone MG
    Semin Cancer Biol; 2017 Jun; 44():106-116. PubMed ID: 28442298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of tumor markers and circulating tumors cells in the management of breast cancer.
    Saad A; Abraham J
    Oncology (Williston Park); 2008 Jun; 22(7):726-31; discussion 734, 739, 743-4. PubMed ID: 18619119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
    J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
    Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy.
    Lehner J; Stötzer OJ; Fersching D; Nagel D; Holdenrieder S
    Clin Chim Acta; 2013 Oct; 425():206-11. PubMed ID: 23916787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
    Duffy MJ; Walsh S; McDermott EW; Crown J
    Adv Clin Chem; 2015; 71():1-23. PubMed ID: 26411409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.
    Kristiansen S; Jørgensen LM; Hansen MH; Nielsen D; Sölétormos G
    Biomed Res Int; 2015; 2015():986024. PubMed ID: 26339655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumour markers in breast cancer.
    Seregni E; Coli A; Mazzucca N;
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S15-22. PubMed ID: 15127239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
    Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
    Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of serum tumor markers for the diagnosis and follow-up of breast cancer.
    Barrenetxea G; Schneider J; Llorente MF
    Oncology; 1998; 55(5):447-9. PubMed ID: 9732223
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up.
    Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Dombernowsky P
    Clin Chem; 1996 Apr; 42(4):564-75. PubMed ID: 8605674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in the treatment of cancer: opportunities and pitfalls.
    Melichar B
    Clin Chem Lab Med; 2013 Jul; 51(7):1329-33. PubMed ID: 23729626
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
    Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
    Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
    Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
    Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor markers in breast cancer: accepted utilities and novel prospects.
    Stearns V; Yamauchi H; Hayes DF
    Breast Cancer Res Treat; 1998; 52(1-3):239-59. PubMed ID: 10066086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.